Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 6.65%, which has investors questioning if this is right time to ...

Limited’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from the National Medical ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ ...

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Wells Fargo notes that Summit Therapeutics (SMMT) partner Akeso (AKESF) received approval from China’s NMPA for ivonescimab as a monotherapy ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in ...

Both U.S.-based Summit Therapeutics (NASDAQ: SMMT) and BioNTech (NASDAQ: BNTX) were down significantly, plunging 36.1% and 15 ...

11) Exelexis' zanzalintinib (XL092), a tyrosine kinase inhibitor targeting VEGF receptors, MET, and TAM kinases that is currently in phase 3 testing for colorectal cancer, renal cell carcinoma ...

BioNTech SE  (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies, next-generation ...